Sequestration of the short and long isoforms of dopamine D2 receptors expressed in Chinese hamster ovary cells

Molecular Pharmacology

Volumn 49, Issue 3, 1996, Pages 560-566

  Itokawa, Masanari ^a   Toru, Michio ^a   Ito, Kazumitsu ^b   Tsuga, Hirofumi ^b   Kameyama, Kimihiko ^b   Haga, Tatsuya ^b   Arinami, Tadao ^c   Hamaguchi, Hideo ^c  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; RECEPTOR SUBTYPE; SPIPERONE; SULPIRIDE;

ANIMAL CELL; ARTICLE; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG COMPETITION; DRUG RECEPTOR BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BASE SEQUENCE; BINDING SITES; CHO CELLS; CRICETINAE; DNA, COMPLEMENTARY; DOPAMINE; DOPAMINE ANTAGONISTS; ISOMERISM; KINETICS; MOLECULAR SEQUENCE DATA; RECEPTORS, DOPAMINE D2; SPIPERONE; SULPIRIDE; TRITIUM;

EID: 0029871818     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. 3H]dihydroergocryptine binding with the dopaminergic control of prolactin release. J. Biol. Chem. 253:2244-2253 (1978).
2. Lee, T., P. Seeman, A. Rajput, I. J. Farley, and O. Hornykiewicz. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature (Lond.) 273:59-61 (1978).
3. Smith, S. S., B. F. O'Hara, A. M Persico, D. A. Gorelick, D. B. Newlin, D. Vlahov, L. Solomon, R. Pickens, and G. R. Uhl. Genetic vulnerability to drug abuse. Arch. Gen. Psychiatry 49:723-727 (1992)
4. Seeman, P. Dopamine receptors, and the dopamine hypothesis of schizophrenia. Synapse 1:133-152 (1987).
5. Kebabian, J. W., and D. B. Calne. Multiple receptors for dopamine. Nature (Lond.) 277:93-96 (1979).
6. Sunahara, R. K., H. B. Niznik, D. M. Weiner, T. M Stormann, M. R. Brann, J. L. Kennedy, J. E. Gelernter, R. Rozmahel, Y. L. Yang, Y. Israel, P. Seeman, and B F. O'Dowd. Human dopamine D1 receptor encoded by an intronless gene on chromosome 5. Nature (Lond.) 347:80-83 (1990).
7. Grandy, D. K., M A. Marchionni, H. Makam, R. E. Stofko, M. Alfano, L. Frothingham, J. B. Fischer, H. K. Burke, J. R. Bunzow, A. C. Server, and O. Civelli. Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc. Natl. Acad. Sci. USA 86:9762-9766 (1989).
8. Sokoloff, P., B. Giros, M. P. Martres, M. L. Bouthenet, and J. C. Schwartz. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neurolepties. Nature (Lond.) 347:146-151 (1990).
9. Van Tol, H., J. R. Bunzow, H. C. Guan, R. K. Sunahara, P. Seeman, H. B. Niznik, and O. Civelli. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic dozapine. Nature (Lond.) 350:610-614 (1991).
10. Sunahara, R K., H. C. Guan, B. F. O'Dowd, P. Seeman, L. G. Laurier, G. Ng, S. R. George, J. Torchia, H. Van Tol, and H. B. Niznik. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature (Lond.) 350:614-619 (1991).
11. Civelli, O., J. R. Bunzow, and D. K. Grandy. Molecular diversity of the dopamine receptors. Annu. Rev. Pharmacol. Toxicol. 33:281-307 (1993).
12. Seeman, P. Dopamine receptor sequences: therapeutic levels of neurolepties occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 7:261-284 (1992).
13. Monsma, F. J., L. D. McVittie, C. R. Gerfen, L. C. Mahan, and D. R. Sibley. Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature (Lond.) 342:926-929 (1989).
14. Liu, Y. F., K. H. Jakobs, M. M. Rasenick, and P. R. Albert. G protein specificity in receptor-effector coupling. J. Biol. Chem. 269:13880-13886 (1994).
15. Montmayeur, J. P., J. Guiramand., and E. Borrelli. Preferential coupling between dopamine D2 receptors and G-proteins. Mol. Endocrinol. 7:161-170 (1993).
16. Shapiro, R. A., and N. M. Nathanson. Deletion analysis of the mouse m1 muscarinic acetylcholine receptor: effects on phosphoinositide metabolism and down-regulation. Biochemistry 28:8946-8950 (1989).
17. Maeda, S., J. Lameh, W. G. Mallet, M. Philip, J. Ramachandran, and W. Sadee. Internalization of the Hm1 muscarinic cholinergic receptor involves the third cytoplasmic loop. FEBS Lett. 269:386-388 (1990).
18. Agui, T., N. Amlaiky, M. G. Caron, and J. W. Kebabian. Agonist-induced desensitization of the D-2 dopamine receptor in the intermediate lobe of the rat pituitary gland. J. Biochem. 103:436-441 (1988).
19. 1 site. Mol. Pharmacol. 34:148-156 (1988).
20. 2 dopamine receptors in human Y-79 retinoblastoma cells. Mol. Pharmacol. 39:650-658 (1991).
21. 2 dopamine receptor by receptor desensitization and adenylyl cyclase sensitization. Mol. Pharmacol. 39:55-63 (1990).
22. 2 receptors in a novel cell line (SUP1). Mol. Pharmacol. 39:531-539 (1991).
23. Flitz, T. M., R. P. Artymyshyn, W. Guan, and P. B. Molinoff. Paradoxical regulation of dopamine receptors in transfected 293 cells. Mol. Pharmacol. 44:371-379 (1993).
24. 2L dopamine receptor isoforms are differentially regulated in Chinese hamster ovary cells. Mol. Pharmacol. 45:878-889 (1994).
25. Itokawa, M., T. Arinami, N. Futamura, H. Hamaguchi, and M. Toru. A structural polymorphism of human dopamine D2 receptor, D2(Ser311→Cys). Biochem. Biophys. Res. Commun. 196:1369-1375 (1993).
26. Arinami, T., M. Itokawa, H. Enguchi, H. Tagaya, S. Yano, H. Shimizu, H. Hamaguchi, and M. Toru. Association of dopamine D2 receptor molecular variant with schizophrenia. Lancet 343:703-704 (1994).
27. Chen, C., and H. Okayama High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7:2745-2752 (1987)
28. Seeman, P. Dopamine receptor sequences. Neuropsychopharmacology 7:261-284 (1992)
29. Norman, J. A., A. H. Drummond, and P. Moser. Inhibition of calcium-dependent regulator-stimulated phosphodiesterase activity by neuroleptic drugs is unrelated to their clinical efficacy. Mol. Pharmacol. 16:1089-1094 (1979).
30. 125I]iodosulpride, a highly selective ligand. Science (Washington D. C.) 228:752-755 (1985).
31. Hausdorff, W. P., M. G. Caron, and R. J. Lefkowitz. Turning off the signal: desensitization of beta-adrenergic receptor function. FASEB J. 4:2881-2889 (1990).
32. Feigenbaum, P., and F. E. El Fakahany. Regulation of muscarinic cholinergic receptor density in neuroblastoma cells by brief exposure to agonist: possible involvement in desensitization of receptor function. J. Pharmacol. Exp. Ther. 233:134-140 (1985).
33. Harden, T. K., L. A. Petch, S. F. Traynelis, and G L. Waldo. Agonist-induced alteration in the membrane form of muscarinic cholinergic receptors. J. Biol. Chem. 260:13060-13066 (1985).
34. Stadel, J. M., B. Strulovici, P. Nambi, T N. Lavin, M M. Briggs, M. G. Caron, and R. J. Lefkowitz. Desensitization of the β-adrenergic receptor of frog erythrocytes: recovery and characterization of the down-regulated receptors in sequestered vesicles. J. Biol. Chem. 258:3032-3038 (1983).
35. Lameh, J., M. Philip, Y. K. Sharma, O. Moro, J. Ramachandran, and W. Sadee. Hm1 muscarinic cholinergic receptor internalization requires a domain in the third cytoplasmic loop J. Biol. Chem. 267:13406-13412 (1992).
36. Tsuga, H., K. Kameyama, T. Haga, H. Kurose, and T. Nagao. Sequestration of muscarinic acetylcholine receptor m2 subtypes: facilitation by G protein-coupled receptor kinase (GRK2) and attenuation by a dominant-negative mutant of GRK2. J. Biol. Chem 269:32522-32527 (1994)
37. Moro, O., J. Lameh, and W. Sadee. Serine- and threonine-rich domain regulates internalization of muscarinic cholinergic receptors. J. Biol. Chem. 268:6862-6865 (1993).
38. Green, S. A., and S. B. Liggett A proline-rich region of the third intracellular loop imparts phenotypic β1- versus β2-adrenergic receptor coupling and sequestration. J. Biol. Chem 269:26215-26219 (1994).
39. Nothen, M. M., D. Wildenauer, S. Cichon, M. Albus, W. Maier, J. Minges, D. Lichtermann, B. Bondy, M. Rietschel, and J. Komer. Dopamine D2 receptor molecular variant and schizophrenia. Lancet 343:1301-1302 (1994).
40. Sobell, J., D. C. Sigurdson, L. Heston, and S. Sommer. S311C D2DR variant: no association with schizophrenia. Lancet 344:621-622 (1994).
41. Nanko, S., M. Hattori, X. Y. Dai, R. Fukuda, and H. Kazamatsuri. DRD2 Ser311/Cys311 polymorphism in schizophrenia. Lancet 343:1044 (1994).
42. Asherson, P., N. Williams, E. Roberts, M. McGuffin, and M. Owen. DRD2 Ser311/Cys311 polymorphism in schizophrenia. Lancet 343:1045 (1994).
43. Shaikh, S., D. Collier, M. Arranz, D. Ball, M. Gill, and R. Kerwin. DRD2 Ser311/Cys311 polymorphism in schizophrenia. Lancet 343:1045-1046 (1994).
44. Laurent, C., S. Bdeau-Pean, D. Campion, T. d'Amato, M. Jay, S. Dollfus, F. Thibault, M. Petit, D. Samolyk, M. Martinez, and J. Mallet. No major role for the dopamine D2 receptor Ser→Cys311 mutation in schizophrenia. Psychiatr. Genet. 4:229-230 (1994)
45. Higuchi, S., T. Muramatsu, M. Murayama, and M. Hayashida. Association of structural polymorphism of the dopamine D2 receptor gene and alcoholism. Biochem. Biophys. Res. Commun. 204:1199-205 (1994).
46. Yu, S. S., R. J. Lefkowitz, and W. P. Hausdorff. β-adrenergic receptor sequestration: a potential mechanism of receptor resensitization. J. Biol. Chem. 268:337-341 (1993).